Journal: Annals of the Rheumatic Diseases

Abbreviation

Ann Rheum Dis

Publisher

BMJ

Journal Volumes

ISSN

0003-4967
1468-2060

Description

Filters

Reset filters

Search Results

Publications 1 - 10 of 12
  • Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study
    Item type: Journal Article
    Abtahi, Shahab; Driessen, Johanna H.M.; Burden, Andrea; et al. (2020)
    Annals of the Rheumatic Diseases
    Background Patients with rheumatoid arthritis (RA) commonly use oral glucocorticoids (GCs) and proton pump inhibitors (PPIs), both associated with osteoporotic fractures. We investigated the association between concomitant use of oral GCs and PPIs and the risk of osteoporotic fractures among patients with RA. Methods This was a cohort study including patients with RA aged 50+ years from the Clinical Practice Research Datalink between 1997 and 2017. Exposure to oral GCs and PPIs was stratified by the most recent prescription as current use (<6 months), recent use (7–12 months) and past use (>1 year); average daily and cumulative dose; and duration of use. The risk of incident osteoporotic fractures (including hip, vertebrae, humerus, forearm, pelvis and ribs) was estimated by time-dependent Cox proportional-hazards models, statistically adjusted for lifestyle parameters, comorbidities and comedications. Results Among 12 351 patients with RA (mean age of 68 years, 69% women), 1411 osteoporotic fractures occurred. Concomitant current use of oral GCs and PPIs was associated with a 1.6-fold increased risk of osteoporotic fractures compared with non-use (adjusted HR: 1.60, 95% CI: 1.35 to 1.89). This was statistically different from a 1.2-fold increased osteoporotic fracture risk associated with oral GC or PPI use alone. Most individual fracture sites were significantly associated with concomitant use of oral GCs and PPIs. Among concomitant users, fracture risk did not increase with higher daily dose or duration of PPI use. Conclusions There was an interaction in the risk of osteoporotic fractures with concomitant use of oral GCs and PPIs. Fracture risk assessment could be considered when a patient with RA is co-prescribed oral GCs and PPIs.
  • Primary and secondary non-response: in need of operational definitions in observational studies
    Item type: Other Journal Item
    Vallejo-Yagüe, Enriqueta; Keystone, Edward C.; Kandhasamy, Sreemanjari; et al. (2021)
    Annals of the Rheumatic Diseases
  • SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance
    Item type: Journal Article
    Niederer, Fabienne; Ospelt, Caroline; Brentano, Fabia; et al. (2011)
    Annals of the Rheumatic Diseases
  • Inhibition of Rac1 activity by controlled release of NSC23766 from chitosan microspheres effectively ameliorates osteoarthritis development in vivo
    Item type: Journal Article
    Zhu, Shouan; Lu, Ping; Liu, Huanhuan; et al. (2015)
    Annals of the Rheumatic Diseases
    Background Osteoarthritis (OA) is a degenerative joint disease characterised by cartilage degradation and chondrocyte hypertrophy. A recent study showed that Rac1 promoted expression of MMP13 and chondrocyte hypertrophy within the growth plate. These findings warrant further investigations on the roles of Rac1 in OA development and therapy in animal models. Objective To investigate the role and mechanistic pathway of Rac1 involvement in pathological changes of OA chondrocytes in vitro and OA development in vivo, as well as to develop a strategy of modulating Rac1 activity for OA treatment. Material and methods OA and normal cartilage from human or mice were used for immunohistochemical study and Rac1 activity assay. Chondrocytes treated with IL1β and the untreated control were subjected to the Rac1 activity assay. Chondrocytes transfected with CA-Rac1, DN-Rac1 or GFP were cultured under conditions for inducing calcification. To evaluate the effect of Rac1 in OA development, an OA model was created by anterior cruciate ligament transection in mice. CA-Rac1, DN-Rac1 and GFP lentivirus, or NSC23766, were injected intra-articularly. Joints were subjected to histological analysis. Results It was found that there is aberrant Rac1 activation in human OA cartilage. Rac1 activity could also be elevated by IL1β. Additionally, activated Rac1 promoted expression of MMP13, ADAMTS-5 and COLX by chondrocytes, partially through the β-catenin pathway. Moreover, activation of Rac1 in knee joints by CA-Rac1 lentivirus accelerated OA progression, while inhibition of Rac1 activity by DN-Rac1 lentivirus or Rac1 inhibitor NSC23766 delayed OA development. Therefore, we developed a strategy of controlled release of NSC23766 from chitosan microspheres to OA joints, which effectively protected cartilage from destruction. Conclusions These findings demonstrated that Rac1 activity is implicated in OA development. Also, controlled release of Rac1 inhibitor is a promising strategy for OA treatment.
  • DEKAVIL (F8-IL10)
    Item type: Journal Article
    Galeazzi, M.; Bazzichi, L.; Prisco, E.; et al. (2013)
    Annals of the Rheumatic Diseases
  • Association between osteoporosis and statins therapy: the story continues
    Item type: Other Journal Item
    Burden, Andrea; Weiler, Stefan (2021)
    Annals of the Rheumatic Diseases
  • Rheumatoid arthritis synovial fibroblasts are differentially regulated by antagonists activin and follistatin
    Item type: Other Conference Item
    Laitinen, C.; Juurikivi, A.; Lindstedt, K.; et al. (2004)
    Annals of the Rheumatic Diseases
  • Changes in surgical intervention patterns in rheumatoid arthritis over 10 years in one centre
    Item type: Journal Article
    Kolling, Christoph; Herren, D.B.; Simmen, Beat R.; et al. (2009)
    Annals of the Rheumatic Diseases
  • Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2
    Item type: Journal Article
    Schniering, Janine; Benešová, Martina; Brunner, Matthias; et al. (2019)
    Annals of the Rheumatic Diseases
Publications 1 - 10 of 12